Published in Antimicrob Agents Chemother on January 22, 2007
SQ109 targets MmpL3, a membrane transporter of trehalose monomycolate involved in mycolic acid donation to the cell wall core of Mycobacterium tuberculosis. Antimicrob Agents Chemother (2012) 2.41
New drugs against tuberculosis: problems, progress, and evaluation of agents in clinical development. Antimicrob Agents Chemother (2008) 1.50
Discovery and development of SQ109: a new antitubercular drug with a novel mechanism of action. Future Microbiol (2012) 1.27
In vitro interactions between new antitubercular drug candidates SQ109 and TMC207. Antimicrob Agents Chemother (2010) 1.25
Current development and future prospects in chemotherapy of tuberculosis. Respirology (2010) 1.12
Tuberculosis pharmacotherapy: strategies to optimize patient care. Expert Opin Pharmacother (2009) 1.08
Activity of SQ641, a capuramycin analog, in a murine model of tuberculosis. Antimicrob Agents Chemother (2009) 1.07
Pipeline of drugs for related diseases: tuberculosis. Curr Opin HIV AIDS (2013) 1.04
The chemical biology of new drugs in the development for tuberculosis. Curr Opin Chem Biol (2010) 1.03
Discovery of dipiperidines as new antitubercular agents. Bioorg Med Chem Lett (2009) 0.97
Ensuring the involvement of children in the evaluation of new tuberculosis treatment regimens. PLoS Med (2008) 0.92
New approaches in the diagnosis and treatment of latent tuberculosis infection. Respir Res (2010) 0.92
Recent advances in tuberculosis: New drugs and treatment regimens. Curr Respir Med Rev (2013) 0.91
Targeting the mycobacterial envelope for tuberculosis drug development. Expert Rev Anti Infect Ther (2012) 0.90
In vitro characterization of the anti-bacterial activity of SQ109 against Helicobacter pylori. PLoS One (2013) 0.87
Recent advances in the diagnosis and treatment of childhood tuberculosis. J Nat Sci Biol Med (2015) 0.82
Terpenyl-purines from the sea. Mar Drugs (2009) 0.80
Antituberculosis therapy for 2012 and beyond. Expert Opin Pharmacother (2012) 0.80
New drugs to treat tuberculosis. F1000 Med Rep (2012) 0.78
New drugs and regimens for treatment of TB. Expert Rev Anti Infect Ther (2010) 0.77
Synergistic interactions of MmpL3 inhibitors with antitubercular compounds in vitro. Antimicrob Agents Chemother (2017) 0.75
A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis. Science (2004) 13.04
The transcriptional responses of Mycobacterium tuberculosis to inhibitors of metabolism: novel insights into drug mechanisms of action. J Biol Chem (2004) 4.75
Identification of new diamine scaffolds with activity against Mycobacterium tuberculosis. J Med Chem (2006) 3.75
Preclinical testing of the nitroimidazopyran PA-824 for activity against Mycobacterium tuberculosis in a series of in vitro and in vivo models. Antimicrob Agents Chemother (2005) 3.16
In vitro and in vivo activities of moxifloxacin and clinafloxacin against Mycobacterium tuberculosis. Antimicrob Agents Chemother (1998) 3.02
Bactericidal activity of the nitroimidazopyran PA-824 in a murine model of tuberculosis. Antimicrob Agents Chemother (2005) 2.74
Combinatorial lead optimization of [1,2]-diamines based on ethambutol as potential antituberculosis preclinical candidates. J Comb Chem (2003) 2.63
Low-dose aerosol infection model for testing drugs for efficacy against Mycobacterium tuberculosis. Antimicrob Agents Chemother (1996) 2.43
Identification of a new antitubercular drug candidate, SQ109, from a combinatorial library of 1,2-ethylenediamines. J Antimicrob Chemother (2005) 2.08
Bactericidal activity of increasing daily and weekly doses of moxifloxacin in murine tuberculosis. Antimicrob Agents Chemother (2002) 2.03
Pharmacodynamics and pharmacokinetics of SQ109, a new diamine-based antitubercular drug. Br J Pharmacol (2005) 1.88
Rapid, simple in vivo screen for new drugs active against Mycobacterium tuberculosis. Antimicrob Agents Chemother (2004) 1.52
Synergistic interactions of SQ109, a new ethylene diamine, with front-line antitubercular drugs in vitro. J Antimicrob Chemother (2006) 1.12
Evaluation of rifalazil in long-term treatment regimens for tuberculosis in mice. Antimicrob Agents Chemother (2000) 1.01
Simultaneous estimation of pharmacokinetic properties in mice of three anti-tubercular ethambutol analogs obtained from combinatorial lead optimization. J Pharm Biomed Anal (2004) 1.01
Pharmacoproteomic effects of isoniazid, ethambutol, and N-geranyl-N'-(2-adamantyl)ethane-1,2-diamine (SQ109) on Mycobacterium tuberculosis H37Rv. J Pharmacol Exp Ther (2005) 0.98
Small molecule RITA binds to p53, blocks p53-HDM-2 interaction and activates p53 function in tumors. Nat Med (2004) 5.48
High-resolution genomic profiles define distinct clinico-pathogenetic subgroups of multiple myeloma patients. Cancer Cell (2006) 5.01
The differentiation and stress response factor XBP-1 drives multiple myeloma pathogenesis. Cancer Cell (2007) 3.76
Identification of new diamine scaffolds with activity against Mycobacterium tuberculosis. J Med Chem (2006) 3.75
Combinatorial lead optimization of [1,2]-diamines based on ethambutol as potential antituberculosis preclinical candidates. J Comb Chem (2003) 2.63
Identification of a new antitubercular drug candidate, SQ109, from a combinatorial library of 1,2-ethylenediamines. J Antimicrob Chemother (2005) 2.08
Genomic alterations link Rho family of GTPases to the highly invasive phenotype of pancreas cancer. Proc Natl Acad Sci U S A (2008) 1.92
Pharmacodynamics and pharmacokinetics of SQ109, a new diamine-based antitubercular drug. Br J Pharmacol (2005) 1.88
Rapid, simple in vivo screen for new drugs active against Mycobacterium tuberculosis. Antimicrob Agents Chemother (2004) 1.52
New tuberculosis vaccine development. Expert Opin Biol Ther (2002) 1.38
In vitro antimycobacterial activities of capuramycin analogues. Antimicrob Agents Chemother (2007) 1.37
The PTEN and INK4A/ARF tumor suppressors maintain myelolymphoid homeostasis and cooperate to constrain histiocytic sarcoma development in humans. Cancer Cell (2006) 1.30
Discovery and development of SQ109: a new antitubercular drug with a novel mechanism of action. Future Microbiol (2012) 1.27
In vitro interactions between new antitubercular drug candidates SQ109 and TMC207. Antimicrob Agents Chemother (2010) 1.25
Synergistic interactions of SQ109, a new ethylene diamine, with front-line antitubercular drugs in vitro. J Antimicrob Chemother (2006) 1.12
PrimaTB STAT-PAK assay, a novel, rapid lateral-flow test for tuberculosis in nonhuman primates. Clin Vaccine Immunol (2007) 1.11
Activity of SQ641, a capuramycin analog, in a murine model of tuberculosis. Antimicrob Agents Chemother (2009) 1.07
Temporal association between expanded HIV testing and improvements in population-based HIV/AIDS clinical outcomes, District of Columbia. AIDS Care (2013) 1.06
Interspecies pharmacokinetics and in vitro metabolism of SQ109. Br J Pharmacol (2006) 1.01
Simultaneous estimation of pharmacokinetic properties in mice of three anti-tubercular ethambutol analogs obtained from combinatorial lead optimization. J Pharm Biomed Anal (2004) 1.01
Making vaccines "on demand": a potential solution for emerging pathogens and biodefense? Hum Vaccin Immunother (2013) 1.00
Discovery of dipiperidines as new antitubercular agents. Bioorg Med Chem Lett (2009) 0.97
In vitro antimicrobial activities of capuramycin analogues against non-tuberculous mycobacteria. J Antimicrob Chemother (2010) 0.94
Chemical modification of capuramycins to enhance antibacterial activity. J Antimicrob Chemother (2010) 0.93
Identification of SQ609 as a lead compound from a library of dipiperidines. Bioorg Med Chem Lett (2011) 0.93
In search of new cures for tuberculosis. Med Chem (2007) 0.90
915 MHz microwaves and 50 Hz magnetic field affect chromatin conformation and 53BP1 foci in human lymphocytes from hypersensitive and healthy persons. Bioelectromagnetics (2005) 0.90
In vitro characterization of the anti-bacterial activity of SQ109 against Helicobacter pylori. PLoS One (2013) 0.87
EBV-encoded EBNA-5 associates with P14ARF in extranucleolar inclusions and prolongs the survival of P14ARF-expressing cells. Int J Cancer (2003) 0.86
The American cotton rat: a novel model for pulmonary tuberculosis. Tuberculosis (Edinb) (2006) 0.86
Preclinical study of new TB drugs and drug combinations in mouse models. Recent Pat Antiinfect Drug Discov (2008) 0.85
SQ109 and PNU-100480 interact to kill Mycobacterium tuberculosis in vitro. J Antimicrob Chemother (2012) 0.81
Generation of a novel nucleic acid-based reporter system to detect phenotypic susceptibility to antibiotics in Mycobacterium tuberculosis. MBio (2012) 0.81
Anti-tuberculosis drug therapy in mice of different inbred strains. Infect Genet Evol (2010) 0.78
Design and optimization of a recombinant system for large-scale production of the MPT64 antigen from Mycobacterium tuberculosis. Protein Expr Purif (2005) 0.77
Therapeutic efficacy of SQ641-NE against Mycobacterium tuberculosis. Antimicrob Agents Chemother (2013) 0.76
Site migration in seeking care services from multiple providers is associated with worse clinical outcomes among HIV-infected individuals in Washington, DC. AIDS Care (2014) 0.75